Prolynx

@ProLynxInc

Developing ultra-long-acting medicines for obesity and metabolic disease, with monthly and quarterly dosing designed for more consistent long-term treatment.

San Francisco Katılım Ağustos 2024

27 Takip Edilen5 Takipçiler

Prolynx@ProLynxInc·11 Ara

Prolynx has raised a $70M Series A & appointed Chris Boulton as CEO. Backed by @5amventures, @OrbiMed, and Monograph Capital, we’re advancing ultra-long-acting therapies designed for monthly and quarterly dosing in obesity & metabolic diseases. More: bit.ly/48xFMY3

English

Prolynx@ProLynxInc·22 Ağu

Check out our recent preprint on bioRxiv! The limitation of lipidation: conversion of semaglutide from once-weekly to once-monthly dosing biorxiv.org/content/10.110…

English

Keşfet

@5amVentures @OrbiMed @elonmusk @BarackObama @taylorswift13 @cristiano @BillGates @NASA